Sponsors Want Answers On Consequences Of Missing US FDA Trial Diversity Goals
Executive Summary
No negative actions have been taken in the US FDA’s oncology review divisions, but vague diversity guidance continues to raise concerns.
You may also be interested in...
NIH Would ‘Revolutionize’ Cancer Trial Recruitment With New ‘Moonshot’ Money
Rick Pazdur's wish for the National Cancer Institute to help industry speed US trial enrollment and diversity could get a boost if Congress fulfills Biden’s new fiscal year Cancer Moonshot funding request.
Payers, Medical Journals Could Help Push For Clinical Trial Diversity, Cavazzoni Says
The director of the US FDA’s Center for Drug Evaluation and Research acknowledged that the FDA cannot improve trial diversity alone.
China Rhetoric Could Be Key To US FDA IT System Upgrade
FDA Commissioner Robert Califf says mentioning China helps increase congressional support.